BRKR
$33.74
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions.
Intraday
Recent News
Will Bruker (BRKR) be Able to Rebound?
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. Despite strong results […]
Bio-Techne, Bruker, DexCom, STERIS, and Teleflex Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.
Research Tools & Consumables Stocks Q4 In Review: Bruker (NASDAQ:BRKR) Vs Peers
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Bruker (NASDAQ:BRKR) and the rest of the research tools & consumables stocks fared in Q4.
Bruker (BRKR): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, Bruker has been a great trade, beating the S&P 500 by 16%. Its stock price has climbed to $41.37, representing a healthy 23.2% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Is Bruker (BRKR) Now Offering Value After A Prolonged Share Price Slump?
If you are wondering whether Bruker stock is starting to look attractive after a rough patch, a closer look at what you are paying for each dollar of value is the right next step. The share price closed at US$39.89, with returns of 0.3% over 7 days but declines of 17.7% over 30 days, 17.1% year to date, 20.6% over 1 year, 40.3% over 3 years and 33.7% over 5 years, which may have changed how the market views its risk and return profile. Recent coverage has focused on Bruker in broader...